PTO/SB/21 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 Please type a plus sign (+) inside this box -> + U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/931.375 **Application Number** TRANSMITTAL August 17, 2001 CATE TRADE **Filing Date FORM** Matthew L. WARMAN et al. **First Named Inventor** (to be used for all correspondence after initial filing) Group Art Unit 1645 **Examiner Name** Unassigned Total Number of Pages in This Submission Attorney Docket Number 38464-0004 ENCLOSURES (check all that apply) After Allowance Communication to **Assignment Papers** Fee Transmittal Form (for an Application) Group Appeal Communication to Board of Fee Attached Drawing(s) Appeals and Interferences Appeal Communication to Group Amendment / Response Licensing-related Papers (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Status Letter Affidavits/declaration(s) Provisional Application Power of Attorney, Revocation Other Enclosure(s) Extension of Time Request Change of Correspondence Address (please identify below): Form PTO/SB/08A (w/6 Terminal Disclaimer References) Express Abandonment Request Request for Refund CD, Number of CD(s) ☐ Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Ł SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Patricia D. Granados, Reg. No. 33,683 Individual name Signature Date CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: Typed or printed name Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT TRADEMARK OFFICE

RECEIVED

OCT 1 5 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Attorney Docket No.: 38464-0004

Applicant:

Matthew L. WARMAN et al.

Confirmation No. 1602

Appl. No.:

09/931,375

Examiner: Unassigned

Filing Date:

August 17, 2001

Art Unit: 1645

Title:

REGULATOR GENE AND SYSTEM USEFUL FOR THE DIAGNOSIS

AND THERAPY OF OSTEOPOROSIS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima* facie prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The relevance of documents B01-B06 are described in the PCT International Search Report, a copy of which is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: October 11, 2002

HELLER EHRMAN WHITE &

MCAULIFFE

1666 K Street, N.W., Suite 300

Washington, DC 20006

Telephone:

(202) 912-2142

Facsimile:

(202) 912-2020

Patricia D. Granados Attorney for Applicant Registration No. 33,683

Customer No. 26633

							_	
Please	type a	pius	sign	(+)	inside	this	box_	

OCT 1 1 2002

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, not desons are required respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

AUE	Complete if Known		
Application Number	09/931,375		
Filing Date	August 17, 2001		
First Named Inventor	Matthew L. WARMAN et al.		
Group Art Unit	1645		
Examiner Name	Unassigned		
Attorney Docket Number	38464-0004		

	U.S. PATENT DOCUMENTS							
5		U.S. Patent Document		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials •	Cite No.1	Number Kind Cod	_	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
	B01	5,913,884		Trauner et al.	06/22/99			
	B02	6,403,637	B1	Partridge.	06/11/02			
	B03	2002/0032157	A1	Giachelli et al.	03/14/02			

	For	eign Patent Doc	ument	Name of Patentee or	Date of Dublication	Pages, Columns,	
Examiner Cite No.1 Office3 Nu	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	Passages ant Figures	
B04	wo	98/42751	A1	Leicester	10/01/1998		
B05	wo	01/77327	A1	Genome Therapeutics Corporation	10/18/2001		
	-				-	_	
	No. ¹ B04	Cite No.1 Office ³ B04 WO	Cite No.1 Office ³ Number ⁴ B04 WO 98/42751	No.¹ Office³ Number⁴ Kind Code⁵ (if known) B04 WO 98/42751 A1	Cite No.1 Office³ Number⁴ Kind Code⁵ (if known) B04 WO 98/42751 A1 University of Leicester Genome	Cite No.1 Office Number Kind Code (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY B04 WO 98/42751 A1 University of Leicester Genome	Cite No.1 Office Number Kind Code (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY Relevant Passages or Relevant Figures Appear B04 WO 98/42751 A1 University of Leicester Genome

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 2023

ECH CENTER 1600/2900

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Please type a plus sign (+) inside this box	+>	PTO/SB/08A (08-00
r lease type a plus sign (1) maide this box		1 1010010011 (00-00

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO					Complete if Known				
) LICO	DRAATI	ON DIC	OL OCUPE	Application Number	09/931,375				
INFORMATION DISCLOSURE				Filing Date	August 17, 2001				
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Matthew L. WARMAN et al.	- (
				Group Art Unit	1645				
7	(use as ma	ny sheets as	necessary)	Examiner Name	Unassigned				
Sheet	2	of	2	Attorney Docket Number	38464-0004				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	B06	DONG, Yu et al., "Molecular Cloning and Characterization of LR3, a Novel LDL Receptor Family Protein with Mitogenic Activity," Biochemical and Biophysical Research Communications 251, pgs. 784-790 (1998) Article No. RC989545, Academic Press, San Diego, CA, USA	
<u>.</u>			

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.